OClawVPS.com
Aulos Bioscience
Edit

Aulos Bioscience

https://www.aulosbio.com/
Last activity: 29.04.2025
Active
Categories: Care
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Mentions
34
Location: United States, California, Larkspur
Total raised: $20M
Email

Investors 1

Funding Rounds 1

DateSeriesAmountInvestors
01.08.2023Series A$20MApple Tree...

Mentions in press and media 34

DateTitleDescription
29.04.2025Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual MeetingData show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors AU-007’s unique clinical activity includes CD8 effector T c...
14.04.2025Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of MelanomaLARKSPUR, Calif., April 14, 2025 – Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of immune-activating antibody therapeutics, today announced dosing of its first patient with a combina...
25.03.2025Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting-
27.11.2024Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer-
07.11.2024Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual MeetingPhase 1 and preliminary Phase 2 data for AU-007 with low-dose aldesleukin show clinical activity, durable Treg reduction and correlated progression-free survival Melanoma and non-small cell lung cancer prioritized for further Phase 2 clinic...
23.10.2024Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsAU-007 demonstrates continued distinction in IL-2 class, with unique profile of Treg reduction and correlated longer PFS outcomes, coupled with increases in tumor-killing Teffs Phase 2 clinical efficacy and safety data to be presented befor...
09.10.2024Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsLARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced that pharmacokinetic data for evaluatio...
04.10.2024Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingLARKSPUR, Calif., October 4, 2024 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of continued promisin...
23.05.2024Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual MeetingPreliminary results show durable anti-tumor activity in multiple solid tumor types among heavily pre-treated patients, including patients whose tumors have progressed through checkpoint inhibitors The results confirm the ability of AU-007, ...
15.05.2024Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007Combination of novel IL-2 therapeutic AU-007, Bavencio® (avelumab) and aldesleukin in Phase 2 cohort of AU-007 clinical trial to build on compelling preclinical evidence of eradication of solid tumors LARKSPUR, Calif., May 15, 2024 – Aulos ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In